Synapse

← Paul M. Ridker

Papers by Paul M. Ridker

Page 1 · newest first

  1. From CANTOS to CIRT to COLCOT to Clinic: Will All Atherosclerosis Patients Soon Be Treated With Combination Lipid-Lowering and Inflammation-Inhibiting Agents?Circulation · 2020
  2. The Pooled Cohort Equations 3 Years OnCirculation · 2016
  3. Interleukin-6 Inhibition with Ziltivekimab for Atherosclerotic DiseaseNew England Journal of Medicine · 2026
  4. Targeting innate immunity-driven inflammation in CKD and cardiovascular diseaseNature Reviews Nephrology · 2022
  5. Statins for the “SMuRFLess But Inflamed”JACC Basic to Translational Science · 2025
  6. The Time to Initiate Anti-Inflammatory Therapy for Patients With Chronic Coronary Atherosclerosis Has ArrivedCirculation · 2023
  7. C-Reactive ProteinCirculation · 2003
  8. A Polygenic Risk Score to Predict Incident Heart Failure Across the Spectrum of Cardiovascular RiskJournal of the American College of Cardiology · 2025
  9. Colchicine for Cardiovascular DiseaseJournal of the American College of Cardiology · 2025
  10. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trialsThe Lancet · 2015
  11. A Quantitative Model to Estimate Free Il-6 Levels Among Participants Treated With the Il-6 Ligand Inhibitor Ziltivekimab: Implications for the Zeus, Hermes, and Artemis TrialsAtherosclerosis · 2026
  12. Oral Nlrp3 Inhibitor Ruvonoflast Provides Rapid, Robust and Reversible Inflammation Reduction in People With Residual Inflammatory Risk of AscvdAtherosclerosis · 2026
  13. Meat Intake, Metabolic Variation, and Cardiovascular Disease Risk in WomenAtherosclerosis · 2026
  14. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trialThe Lancet · 2009
  15. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trialsThe Lancet · 2023
  16. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of DiabetesJournal of the American College of Cardiology · 2018
  17. C-Reactive Protein as a Risk PredictorCirculation · 2006
  18. C-Reactive Protein and Other Emerging Blood Biomarkers to Optimize Risk Stratification of Vulnerable PatientsJournal of the American College of Cardiology · 2006
  19. Anthocyanin and Blueberry Intake, Lipids, C‐Reactive Protein, and the Risk of Cardiovascular Disease in WomenJournal of the American Heart Association · 2026
  20. Universal screening for hsCRP in patients with atherosclerotic disease: a Major therapeutic opportunityEuropean Heart Journal · 2024
  21. A stitch in time: easily measured biomarkers to enhance cardiovascular risk prediction in primary preventionEuropean Heart Journal · 2025
  22. When the exposure causes selection bias: understanding why risk factors attenuate in secondary as compared with primary prevention and what to do about itEuropean Heart Journal · 2026
  23. Genetic Risk of Cardiovascular Disease Among People With No Standard Modifiable Risk FactorsJACC Advances · 2026
  24. Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney DiseaseJournal of the American College of Cardiology · 2018
  25. Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary AnalysisCirculation · 2026
  26. Comparable 4-Year Stability for High-Sensitivity C-Reactive Protein and LDL CholesterolJournal of the American College of Cardiology · 2026
  27. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)American Heart Journal · 2011
  28. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trialThe Lancet · 2012
  29. Lipoprotein(a) and Cardiovascular Risk Prediction Among WomenJournal of the American College of Cardiology · 2018
  30. Inflammation and AtherothrombosisJournal of the American College of Cardiology · 2006
  31. Lipoprotein(a), Hormone Replacement Therapy, and Risk of Future Cardiovascular EventsJournal of the American College of Cardiology · 2008
  32. Clinical Application of C-Reactive Protein for Cardiovascular Disease Detection and PreventionCirculation · 2003
  33. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trialThe Lancet · 2021
  34. Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction TrialEuropean Heart Journal · 2020
  35. C-Reactive Protein and Risk of Incident Heart Failure in Patients With Cardiovascular DiseaseJournal of the American College of Cardiology · 2023
  36. The value of low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) in guiding cardiovascular preventionEuropean Heart Journal · 2025
  37. Inflammation, Immunity, and Infection in AtherothrombosisJournal of the American College of Cardiology · 2018
  38. A Test in ContextJournal of the American College of Cardiology · 2016
  39. Low-Dose Colchicine for Secondary Prevention of Coronary Artery DiseaseJournal of the American College of Cardiology · 2023
  40. Ziltivekimab in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the ATHENA and HERMES trialsEuropean Journal of Heart Failure · 2026
  41. Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS TrialJournal of the American College of Cardiology · 2020
  42. Triglyceride-Rich Lipoprotein Cholesterol, Small Dense LDL Cholesterol, and Incident Cardiovascular DiseaseJournal of the American College of Cardiology · 2020
  43. ApoA-I Infusions and Burden of Ischemic Events After Acute Myocardial InfarctionJournal of the American College of Cardiology · 2024
  44. The Long- and Short-Term Impact of Elevated Body Mass Index on the Risk of New Atrial FibrillationJournal of the American College of Cardiology · 2010
  45. Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular EventsJournal of the American College of Cardiology · 2014
  46. C-Reactive Protein and the Prediction of Cardiovascular Events Among Those at Intermediate RiskJournal of the American College of Cardiology · 2007
  47. Effect of sleep loss on C-Reactive protein, an inflammatory marker of cardiovascular riskJournal of the American College of Cardiology · 2004
  48. Technology-Assisted Self-Selection of Candidates for Nonprescription Statin TherapyJournal of the American College of Cardiology · 2021
  49. Lipoproteins in chronic kidney disease: from bench to bedsideEuropean Heart Journal · 2020
  50. Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agentsEuropean Heart Journal · 2016